Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vyne Therapeutics Inc VYNE

Healthcare
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its... see more

Recent & Breaking News (NDAQ:VYNE)

VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference

GlobeNewswire September 20, 2021

VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference

GlobeNewswire September 8, 2021

VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases

GlobeNewswire August 12, 2021

VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited

GlobeNewswire August 12, 2021

VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone

GlobeNewswire August 2, 2021

VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021

GlobeNewswire July 27, 2021

VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne

GlobeNewswire July 19, 2021

VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event

GlobeNewswire June 29, 2021

VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021

GlobeNewswire April 28, 2021

VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences

GlobeNewswire March 4, 2021

VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update

GlobeNewswire March 4, 2021

VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference

GlobeNewswire March 1, 2021

VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis

GlobeNewswire March 1, 2021

VYNE Therapeutics to Report Financial Results for the Year Ended December 31, 2020 on March 4

GlobeNewswire February 23, 2021

VYNE Therapeutics Announces Reverse Stock Split

GlobeNewswire February 11, 2021

VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update

GlobeNewswire February 1, 2021

VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update

GlobeNewswire January 29, 2021

VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

GlobeNewswire January 26, 2021

VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company

GlobeNewswire January 21, 2021

VYNE Therapeutics to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this Week

GlobeNewswire January 5, 2021